AUTOLOGOUS BONE MARROW TRANSPLANTS--BREAST/OVARY CANCER

该计划项目赠款评估剂量强化在以下方面的作用： 乳腺癌和卵巢癌的治疗 我们建议使用高剂量 联合使用烷化剂和骨髓支持治疗 诱导化疗后早期转移性乳腺癌 大剂量化疗和骨髓支持， 高风险II期乳腺癌，涉及10个或更多淋巴结， 给予全身性环磷酰胺和塞替派与骨髓支持， 进行高剂量治疗和自体移植的I期和II期试验 卵巢癌的骨髓支持 使用多种单克隆抗体，我们将监测骨髓 参与恶性乳腺癌细胞和发展 免疫药理学方法去除恶性污染。 两个项目将试图改善高剂量的毒性 化疗 我们将使用重组的 粒细胞巨噬细胞集落刺激因子（rHuGM-CSF）在缩短中的作用 高剂量治疗后的骨髓抑制期和自体 骨髓支持，通过进行随机比较试验。 我们将 进行研究以了解难治性的潜在机制 和功能失调性血小板减少症，并评估治疗方法。 这些项目的执行得到三个核心项目的支持， 涉及冷冻保存、统计和管理。

This Program Project Grant evaluates the role of dose-intensification in the treatment of breast and ovarian cancer. We propose to use high dose combination alkylating agents and bone marrow support in the treatment of early metastatic breast cancer following induction chemotherapy with adriamycin and to use high dose chemotherapy and bone marrow support in high risk Stage II Breast cancer involving 10 or more lymph nodes and high dose systemic cyclophosphamide and thiotepa with bone marrow support and to perform phase I and phase II trials of high dose therapy and autologous bone marrow support in ovarian cancer. Using multiple monoclonal antibodies, we will monitor bone marrow for involvement with malignant breast cancer cells and develop immunopharmacologic methods for removing the malignant contamination. Two projects will attempt to ameliorate the toxicity of high dose chemotherapy. We will extend our initial observations using recombinant granulocyte macrophage colony-stimulating-factor (rHuGM-CSF) in shortening the period of myelosuppression following high dose therapy and autologous bone marrow support by performing a randomized, comparative trial. We will perform investigations to understand the mechanism underlying refractory and dysfunctional thrombocytopenia and evaluate the therapeutic approaches. The performance of these projects is supported by three core projects, involving cryopreservation, statistics and administration.